Compare · DVA vs PGNY
DVA vs PGNY
Side-by-side comparison of DaVita Inc. (DVA) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DVA and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- DVA is the larger of the two at $12.72B, about 6.3x PGNY ($2.02B).
- Over the past year, DVA is up 42.4% and PGNY is up 15.1% - DVA leads by 27.3 points.
- PGNY has been more active in the news (25 items in the past 4 weeks vs 12 for DVA).
- PGNY has more recent analyst coverage (25 ratings vs 13 for DVA).
- Company
- DaVita Inc.
- Progyny Inc.
- Price
- $198.06+3.13%
- $25.80-0.58%
- Market cap
- $12.72B
- $2.02B
- 1M return
- -0.32%
- +8.81%
- 1Y return
- +42.39%
- +15.08%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 12
- 25
- Recent ratings
- 13
- 25
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest DVA
- DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Yale Phyllis R gifted 5,038 shares, decreasing direct ownership by 35% to 9,525 units (SEC Form 4)
- Director Pullin Dennis W was granted 250 shares, increasing direct ownership by 10% to 2,671 units (SEC Form 4)
- Director Schoppert Wendy Lee was granted 250 shares (SEC Form 4)
- Director Moore Gregory J. was granted 250 shares, increasing direct ownership by 3% to 7,813 units (SEC Form 4)
- Director Arway Pamela M was granted 250 shares, increasing direct ownership by 0.94% to 26,945 units (SEC Form 4)
- Director Yale Phyllis R was granted 250 shares, increasing direct ownership by 2% to 14,563 units (SEC Form 4)
- Director Hollar Jason M. was granted 250 shares, increasing direct ownership by 4% to 6,605 units (SEC Form 4)
- Director Desoer Barbara J was granted 250 shares (SEC Form 4)
- Director Schechter Adam H was granted 250 shares, increasing direct ownership by 5% to 5,692 units (SEC Form 4)
Latest PGNY
- Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.
- CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 1,421 shares and sold $64,184 worth of shares (2,517 units at $25.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 74,688 units (SEC Form 4) (tax withholding)
- EVP, GC Swartz Allison covered exercise/tax liability with 1,015 shares and sold $45,022 worth of shares (1,798 units at $25.04) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 82,378 units (SEC Form 4) (for withholding tax)
- CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 5,361 shares, decreasing direct ownership by 0.66% to 811,472 units (SEC Form 4) to satisfy tax liability
- CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 158 shares and sold $7,310 worth of shares (279 units at $26.20) as part of a pre-agreed trading plan, decreasing direct ownership by 0.55% to 78,626 units (SEC Form 4) (withholding tax)
- Director Scott Cheryl exercised 14,667 shares at a strike of $13.00, covered exercise/tax liability with 7,228 shares and sold $196,278 worth of shares (7,439 units at $26.39) (SEC Form 4)
- Chief Product Officer Clapp Geoffrey sold $39,137 worth of shares (1,530 units at $25.58), exercised 12,909 shares at a strike of $20.91 and covered exercise/tax liability with 11,379 shares (SEC Form 4) (for tax liability)
- EVP, GC Swartz Allison covered exercise/tax liability with 1,352 shares and sold $61,053 worth of shares (2,398 units at $25.46) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 85,191 units (SEC Form 4) to cover withholding tax
- Director Gordon Kevin K sold $137,445 worth of shares (5,500 units at $24.99), disposed of 2,526 shares and acquired 2,526 shares, decreasing direct ownership by 54% to 6,792 units (SEC Form 4)
- New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System